Determination of Ondansetron in Plasma and Its Pharmacokinetics in the Young and Elderly

Ondansetron is a 5-hydroxytryptamine3 receptor antagonist for the treatment of chemotherapy- and radiotherapy-induced nausea and emesis. A sensitive, accurate, and precise HPLC method for the determination of ondansetron in plasma is described. Samples are prepared by solid-phase extraction and, aft...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 1991-09, Vol.80 (9), p.868-871
Main Authors: Colthup, Philip V., Felgate, Clive C., Palmer, Jonathan L., Scully, Nicholas L.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
Aged
Antiemetics - blood
Antiemetics - pharmacokinetics
Biological and medical sciences
Digestive system
Humans
Imidazoles - blood
Imidazoles - pharmacokinetics
Medical sciences
Ondansetron
Pharmacology. Drug treatments
Serotonin Antagonists - blood
Serotonin Antagonists - pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ondansetron is a 5-hydroxytryptamine3 receptor antagonist for the treatment of chemotherapy- and radiotherapy-induced nausea and emesis. A sensitive, accurate, and precise HPLC method for the determination of ondansetron in plasma is described. Samples are prepared by solid-phase extraction and, after chromatography of the extracts on a silica analytical column, ondansetron is detected by UV absorbance at 305 nm. The method is sensitive down to 1 ng/mL, at which concentration the coefficient of variation was 6.2% in a single assay run. Repeated analyses of quality control samples, nominally at 2 ng/mL, were carried out over a number of assay runs with a coefficient of variation of 5.5%. The method is specific for ondansetron with respect to endogenous plasma components, identified phase I metabolites, and some co-administered chemotherapeutic drugs. In sustained use over several months, and in support of the clinical development of ondansetron, the method has been shown to be robust. An application of the assay in the investigation of the pharmacokinetics of ondansetron in the young and elderly is described.
ISSN:0022-3549
1520-6017
DOI:10.1002/jps.2600800913